Literature DB >> 23000453

Differential expression of miRNAs in rhabdomyosarcoma and malignant rhabdoid tumor.

Sorin Armeanu-Ebinger1, Delia Herrmann, Michael Bonin, Ivo Leuschner, Steven W Warmann, Jörg Fuchs, Guido Seitz.   

Abstract

Alveolar rhabdomyosarcoma (RMA) and malignant rhabdoid tumor (MRT) have a frequent metastatic spread and a poor prognosis. Aberrant miRNA expression is often found in metastatic tumors. The aim of this study was to identify specific miRNA expression patterns in these tumors. We analyzed the expression of miRNAs in RMA and MRT in tissue samples and in the rhabdomyosarcoma (RMS) cell lines (Rh30 and RD). Selected target miRNAs were modulated with mimic or inhibitor oligonucleotides. Functional analysis was monitored by flow cytometry and migration assays. A set of 107 differentially expressed miRNAs showed tissue-specific clustering of RMA and MRT. Comparison with the Sarcoma microRNA Expression Database revealed RMA- and MRT-specific miRNAs. Metastatic invasion associated miRNA miR-9 was overexpressed in RMA. miR-200c-inhibiting migration-was lower expressed in RMA than in MRT. Transient transfection of RMS cells with a miR-200c mimic and miR-9( inhibitor did neither increase the expression of the known target E-cadherin nor decrease migration. Expression of E-cadherin could be induced in RD cells using decitabine, but demethylation did not influence cell migration. Despite a comparable high rate of metastatic invasion pediatric RMA and MRT show a different pattern of miRNA expression possibly allowing risk stratification.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23000453     DOI: 10.1016/j.yexcr.2012.07.015

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

Review 2.  MicroRNAs in the pathobiology of sarcomas.

Authors:  Anne E Sarver; Subbaya Subramanian
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

Review 3.  MicroRNA dysregulation in rhabdomyosarcoma: a new player enters the game.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen; Yang Liu; Matthew T V Chan; William K K Wu
Journal:  Cell Prolif       Date:  2015-07-23       Impact factor: 6.831

4.  MiR-29c inhibits glioma cell proliferation, migration, invasion and angiogenesis.

Authors:  Yue-chao Fan; Peng-jin Mei; Chen Chen; Fa-an Miao; Hui Zhang; Zhong-lin Li
Journal:  J Neurooncol       Date:  2013-08-13       Impact factor: 4.130

Review 5.  MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics.

Authors:  Jyotika Varshney; Subbaya Subramanian
Journal:  Front Mol Biosci       Date:  2015-06-17

Review 6.  MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers.

Authors:  Tomohiro Fujiwara; Toshiyuki Kunisada; Ken Takeda; Koji Uotani; Aki Yoshida; Takahiro Ochiya; Toshifumi Ozaki
Journal:  Biomed Res Int       Date:  2014-08-04       Impact factor: 3.411

7.  Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members.

Authors:  Francesca Megiorni; Samantha Cialfi; Heather P McDowell; Armando Felsani; Simona Camero; Alessandro Guffanti; Barry Pizer; Anna Clerico; Alessandra De Grazia; Antonio Pizzuti; Anna Moles; Carlo Dominici
Journal:  BMC Cancer       Date:  2014-11-25       Impact factor: 4.430

Review 8.  MiRNAs as Players in Rhabdomyosarcoma Development.

Authors:  Patrizia Gasparini; Andrea Ferrari; Michela Casanova; Francesca Limido; Maura Massimino; Gabriella Sozzi; Orazio Fortunato
Journal:  Int J Mol Sci       Date:  2019-11-19       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.